Scilex Holding Co (SCLX) stock

SCLXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLXW

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 1/30

$1.56−0.06 (-3.70%)

Close on Nov 12, 2026Market cap $13.25MP/E –Yield –

Scilex price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Scilex's price to sales ratio was 0.4× on Nov 10, 2026, against 3.0× a year earlier. Over the last 5 years it ranged from 0.4× to 32.1×, with a median of 2.6×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 10, 2026	0.4×	−1.4
2025	Dec 31, 2025	1.8×	+0.8
2024	Dec 31, 2024	1.0×	−3.2
2023	Dec 29, 2023	4.2×	−2.8
2022	Jan 31, 2022	7.0×	+0.0
2021	Dec 31, 2021	7.0×	–

Where these numbers come from

Parsed from the XBRL in Scilex's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-35 reverse split on Apr 15, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SCLX.

Compare: SCLX vs PTHS · SCLX vs TNXP · SCLX vs LENZ · SCLX vs CPIX · SCLX vs LXRX

Revenue growth-28.5% · median 164.3%

Gross margin161.1% · median 89.3%

Operating margin-1136.4% · median -147.4%

Net margin-1469.8% · median -161.8%

Company	Revenue	Growth
PTHS	$51.29M	–
TNXP	$43.05M	+318.0%
LXRX	$38.54M	-45.6%
SCLX	$31.61M	-28.5%
CPIX	$25.13M	+10.7%
LENZ	$21.48M	+329.5%

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 34
Auditor: BPM LLP
SEC CIK: 1820190

Advertisement
300 × 250

See a number that looks wrong?